share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Apr 18 04:05
Summary by Futu AI
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced on April 17, 2024, an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement grants Clearmind exclusive worldwide rights to develop, research, manufacture, market, and commercialize products based on a patent-pending synthesis of Generation 3.0 psychedelic compounds. These compounds are aimed at treating addiction and mental disorders, with a focus on safety and therapeutic potential. The CEO of Clearmind, Dr. Adi Zuloff-Shani, emphasized the company's commitment to innovation and its goal to provide optimized psychedelic medications for patients with unmet needs. The announcement was made in a press release which is also incorporated by reference into the company's Registration Statements on Form F-3 filed with the SEC. Clearmind's shares are traded on Nasdaq and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY0', respectively.
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced on April 17, 2024, an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement grants Clearmind exclusive worldwide rights to develop, research, manufacture, market, and commercialize products based on a patent-pending synthesis of Generation 3.0 psychedelic compounds. These compounds are aimed at treating addiction and mental disorders, with a focus on safety and therapeutic potential. The CEO of Clearmind, Dr. Adi Zuloff-Shani, emphasized the company's commitment to innovation and its goal to provide optimized psychedelic medications for patients with unmet needs. The announcement was made in a press release which is also incorporated by reference into the company's Registration Statements on Form F-3 filed with the SEC. Clearmind's shares are traded on Nasdaq and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY0', respectively.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.